Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson Financials and Guidance Call Transcript

Aug 30, 2023 / NTS GMT
Release Date Price: R$53.31 (+0.66%)
Jessica Moore
Johnson & Johnson - VP of IR

Hello. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to the company's review of our updated financials and 2023 guidance as a company dedicated to pharmaceutical and med tech innovation following the completion of the Kenvue exchange offer. I am joined by Joe Wolk, Executive Vice President, Chief Financial Officer. Before we get started, you can find additional materials, including the associated press release, presentation, transcript and supplemental schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.

Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot